Trending
- OPTIM: a randomized phase II trial of nivolumab followed by nivolumab-ipilimumab or docetaxel at progression in recurrent/metastatic squamous cell carcinoma of the head and neck (OPTIM; AIO-KHT-0117)
- ‘I didn’t think I’d be graduating’ after Freshers’ Week cancer op
- High KPNA2 expression predicts poor prognosis in pathological T4 colorectal cancer by importing c-Myc into the nucleus to suppress p53-dependent p21 expression
- Correspondence on Mauro et al.: ensuring meaningful conclusions through data accuracy and consistency
- 01 Real-World Outcomes of Radiation Omission After Breast-Conserving Surgery in Older Women With Stage I ER-Positive Breast Cancer: A SEER Analysis (2000–2022)
- Comparison of obecabtagene autoleucel versus an external control arm in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia
- OS Does Not Improve With Continuous Vs Fixed Lenalidomide Dosing in NDMM
- How Do Updated NCCN Guidelines and ctDNA Data Reshape MIBC Treatment?
Saturday, July 18